Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Elicio Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Elicio Therapeutics, Inc.

ELTX

Elicio Therapeutics, Inc.

About Elicio Therapeutics, Inc.

Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapies for cancer. Its proprietary AMP technology enhances T cell responses by delivering payloads to lymph nodes. The company’s focus includes off-the-shelf cancer vaccines targeting neoantigens like mutated KRAS, BRAF, and TP53, aiming to improve immune activation and treatment outcomes across various solid tumors. It collaborates with academic institutions and relies on third-party manufacturing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Elicio Therapeutics, Inc.

1
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $11.8 Million Net Loss in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $39.6 Million Net Loss and Advances ELI-002 7P in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $10.1 Million Net Loss in Q3 2025, Decreasing from Previous Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $10.6 Million Net Loss in Q2 2025, Focuses on ELI-002 7P Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $11.2 Million Net Loss in Q1 2025, Seeks Additional Financing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports $51.9 Million Net Loss for 2024, Highlights Merger and Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Elicio Therapeutics, Inc. Elicio Therapeutics Reports Net Loss of $18.8M, Increases Cash Reserves to $26M in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments